• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    The Valens Company Announces Results of Annual General Meeting of Shareholders

    8/3/22 7:00:00 AM ET
    $VLNS
    Get the next $VLNS alert in real time by email

    KELOWNA, BC, Aug. 3, 2022 /PRNewswire/ - The Valens Company Inc. (TSX: VLNS) (NASDAQ:VLNS) (the "Company", "The Valens Company" or "Valens") a leading manufacturer of cannabis products, today announced the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held by way of live audio webcast on August 2, 2022.

    The Valens Company Inc. logo (CNW Group/The Valens Company Inc.)

    Six of the director nominees that were put forward by the Company were elected by shareholders at the Meeting to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. The results of the vote for the election of directors at the Meeting are set out as follows:

    Nominee

    Votes For

    Percent

    Votes Withheld

    Percent

    Guy Beaudin

    20,340,337

    97.59 %

    502,671

    2.41 %

    Andrew Cockwell

    20,609,431

    98.88 %

    233,577

    1.12 %

    Karin AMcCaskill

    20,007,288

    95.99 %

    835,720

    4.01 %

    Ashley McGrath

    19,998,568

    95.95 %

    844,440

    4.05 %

    Tyler Robson

    20,158,064

    96.71 %

    684,943

    3.29 %

    Drew Wolff

    20,532,986

    98.51 %

    310,022

    1.49 %

    KPMG LLP was also reappointed by shareholders at the Meeting. 

    Although extensively vetted by the Nominating and Governance Committee of the Company and initially confirming her ability and interest to stand as a director nominee for election at the Meeting as disclosed in the Management Information Circular dated July 5, 2022, immediately prior to the commencement of the Meeting, Aïda Moudachirou-Rébois advised the Company that due to unanticipated circumstances unrelated to the Company, she is precluded from serving and accordingly had to withdraw her consent.  She was, therefore, not eligible to stand for election to the Board of Directors of the Company (the "Board").

    This Company continues its commitment to governance best practices, including transparency and accountability. The Company will continue to identify and attract additional qualified diverse director candidates to further strengthen the board in key areas, including diversity, CPG marketing and branding and capital markets.

    Full details of the foregoing and results of the Meeting are contained in the Report of Voting Results for the Meeting which is filed under Valens' profile on SEDAR at www.sedar.com.

    At Valens, it's Personal.

    About The Valens Company

    The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company's wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com.  

    Notice regarding Forward Looking Statements

    All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management's expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management's current expectations and plans relating to the future. Wherever possible, words such as "plans", "expects", "scheduled", "trends", "forecasts", "future", "indications", "potential", "estimates", "predicts", "anticipate", "to establish", "believe", "intend", "ability to", or statements that certain actions, events or results "may", "should", "could", "would", "might", "will", or are "likely" to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, statements regarding the ability to regain compliance with the Nasdaq Listing Rules, and anticipated courses of action.

    The risks and uncertainties that may affect forward-looking statements include, among others, the inability to meet the Minimum Bid Requirement or comply with Nasdaq's other listing standards within the prescribed time period, which could result in the delisting of the common shares, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company's latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company's website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management's current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-valens-company-announces-results-of-annual-general-meeting-of-shareholders-301598734.html

    SOURCE The Valens Company Inc.

    Get the next $VLNS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $VLNS

    DatePrice TargetRatingAnalyst
    3/3/2022Market Perform → Underperform
    Raymond James
    More analyst ratings

    $VLNS
    SEC Filings

    See more
    • SEC Form 15-12G filed by The Valens Company Inc.

      15-12G - Valens Company, Inc. (0001859902) (Filer)

      1/27/23 8:12:07 AM ET
      $VLNS
    • SEC Form F-10POS filed by The Valens Company Inc.

      F-10POS - Valens Company, Inc. (0001859902) (Filer)

      1/17/23 10:51:15 AM ET
      $VLNS
    • SEC Form 6-K filed by The Valens Company Inc.

      6-K - Valens Company, Inc. (0001859902) (Filer)

      1/17/23 10:48:49 AM ET
      $VLNS

    $VLNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SNDL Completes Acquisition of The Valens Company

      Creates a low-cost vertically integrated Canadian company generating over a billion dollars in annualized pro forma revenue1 CALGARY, AB, Jan. 17, 2023 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" the "Company") is pleased to announce the completion of the previously disclosed acquisition of all of the issued and outstanding common shares ("Valens Shares") of The Valens Company Inc. (TSX:VLNS) (NASDAQ:VLNS) ("Valens"), other than those held by SNDL and its subsidiaries, pursuant to a plan of arrangement under the Canada Business Corporations Act (the "Transaction"), for tota

      1/17/23 8:32:00 AM ET
      $SNDL
      $VLNS
      Medicinal Chemicals and Botanical Products
      Health Care
    • THE VALENS COMPANY OBTAINS FINAL COURT ORDER APPROVING THE PROPOSED PLAN OF ARRANGEMENT WITH SNDL

      KELOWNA, BC, Jan. 3, 2023 /PRNewswire/ - The Valens Company Inc. (TSX:VLNS) (NASDAQ:VLNS) ("The Valens Company" or "Valens"), a leading manufacturer of cannabis products, is pleased to announce today that the Ontario Superior Court of Justice (Commercial List) has granted a final order approving the previously announced plan of arrangement (the "Arrangement") with SNDL Inc. ("SNDL") under Section 192 of the Canada Business Corporations Act in accordance with the terms of the arrangement agreement between Valens and SNDL dated August 22, 2022. Under the terms of the Arrangement

      1/3/23 1:19:00 PM ET
      $SNDL
      $VLNS
      Medicinal Chemicals and Botanical Products
      Health Care
    • The Valens Company Granted Additional 180 Calendar Day Grace Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule

      KELOWNA, BC, Dec. 13, 2022 /PRNewswire/ - The Valens Company Inc. (TSX:VLNS) (NASDAQ:VLNS) (the "Company", "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, announced today it received an extension of 180 calendar days from the Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Bid Price Requirement"), following the expiration of the initial 180 calendar days period to regain compliance on December 12, 2022. The Nasdaq determination is based on the Company meeting the continued listing requirement for mar

      12/13/22 6:30:00 PM ET
      $VLNS

    $VLNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Valens Co downgraded by Raymond James

      Raymond James downgraded Valens Co from Market Perform to Underperform

      3/3/22 4:41:15 AM ET
      $VLNS

    $VLNS
    Leadership Updates

    Live Leadership Updates

    See more
    • The Valens Company Appoints New Board Chair and Provides an Update on its Annual General Meeting of Shareholders

      KELOWNA, BC, May 16, 2022 /PRNewswire/ - The Valens Company Inc. (TSX: VLNS) (Nasdaq: VLNS)) (the "Company" "The Valens Company" or "Valens"), a leading manufacturer of branded cannabis products, today announced that it has separated the roles of Chair and Chief Executive Officer (CEO) and appointed Andrew Cockwell as its new Chair of the Board, effective immediately.  This decision follows the Company's recent Nasdaq listing and its commitment to governance best practices including transparency and accountability. Tyler Robson has stepped down as Chair in full support of this decision and will remain on the Board and as the CEO of the Company.

      5/16/22 5:00:00 PM ET
      $VLNS

    $VLNS
    Financials

    Live finance-specific insights

    See more
    • Valens Semiconductor to Announce Second Quarter 2022 Financial Results on August 10, 2022

      HOD HASHARON, Israel,, July 20, 2022 /PRNewswire/ -- Valens Semiconductor (NYSE:VLN), a premier provider of high-speed connectivity solutions for the audio-video and automotive markets, today announced that it will release its second quarter 2022 financial results before the market opens on Wednesday, August 10, 2022. In conjunction with this announcement, Valens will host a conference call on Wednesday, August 10, 2022, at 8:30 a.m. Eastern Time (ET) to discuss its second quarter 2022 financial results and business outlook. To access this call, dial +1 (888) 642-5032 (U.S.), 0 (800) 917-5108 (UK), 03 918 0609 (Israel) or +972 3 918 0609 (all other locations). A live webcast of the conferenc

      7/20/22 8:00:00 AM ET
      $VLN
      $VLNS
      Semiconductors
      Technology
    • The Valens Company Reports Second Quarter Fiscal 2022 Financial Results

      Realized initial benefits of Integration Initiatives, with SG&A as a percent of revenue declining 908 basis points in Q2 2022 from Q1 2022 In five months, Valens has actioned $15 million in annual cost savings and has identified in excess of $5 million additional cost savings to be actioned over the next few quarters exceeding management's original $20 million target Achieved double-digit revenue growth in Green Roads, B2B, & International revenue segments. Provincial sales rebounded strongly in June with record monthly revenue Top 10 licensed producer in Canada, with a 3.2% market share for three months ending May 2022 Valens reiterates its objective of achieving positive adjusted EBITDA(2

      7/13/22 5:00:00 PM ET
      $VLNS
    • The Valens Company to Hold Conference Call to Discuss Financial Results for the Second Quarter of 2022

      KELOWNA, BC, July 6, 2022 /PRNewswire/ - The Valens Company Inc. (TSX:VLNS) (NASDAQ:VLNS) (the "Company" "The Valens Company" or "Valens"), a leading manufacturer of cannabis products, is pleased to announce it will issue its second quarter 2022 financial results for the period ended May 31, 2022, on Wednesday, July 13, 2022, after market close. CONFERENCE CALL DETAILS The Company will host a conference call the following day, Thursday, July 14, 2022, at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time to discuss the financial results and business outlook. Participant Dial-In

      7/6/22 5:00:00 PM ET
      $VLNS